LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?

What the latest earnings mean for LeMaitre Vascular stock

LeMaitre Vascular (LMAT) just released second quarter 2026 results that included higher sales, higher net income and updated guidance, along with a reaffirmed cash dividend, giving investors several fresh data points to assess the stock.

See our latest analysis for LeMaitre Vascular.

Despite the stronger second quarter report and updated guidance, LeMaitre Vascular's recent share price performance has been weak, with a 7 day share price return of 21.39% and a 30 day share price return of 20.72% at odds with a 3 year total shareholder return of 47.93% and 5 year total shareholder return of 51.8%. This suggests longer term holders have seen a very different experience from recent buyers.

If this earnings update has you thinking about other opportunities in medical technology, it could be a useful moment to see which healthcare companies are using AI to reshape patient outcomes through the 43 healthcare AI stocks.

LeMaitre Vascular now trades well below both analyst targets and some intrinsic estimates, yet the stock has pulled back over the past year. Is that discount a genuine opportunity or a warning signal about market caution?

Most Popular Narrative: 31.4% Undervalued

At a last close of $81.45, the most followed narrative on LeMaitre Vascular points to a fair value of $118.75. That gap is built on a detailed view of how future earnings, margins and required returns could play out using a 7.61% discount rate.

Strong pipeline of biologics and next-generation products, combined with ongoing regulatory wins, enhances pricing power and product mix. This supports premium pricing and improved gross margins, with successful launches expected to materially contribute to long-term earnings growth.

Read the complete narrative.

Want to see what sits behind that fair value for LeMaitre Vascular? The narrative leans heavily on steady revenue compounding, firm margins and a richer future earnings multiple, all tied together through that 7.61% discount rate and analyst consensus on long term profitability.

Result: Fair Value of $118.75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, LeMaitre Vascular still faces execution risks if international expansion proves slower than expected or if pricing pressure limits the assumed margin resilience.

Find out about the key risks to this LeMaitre Vascular narrative.

Another View on LeMaitre Vascular's Valuation

The analyst narrative points to LeMaitre Vascular trading about 31.4% below an estimated fair value of $118.75. Yet on simple P/E, the stock looks expensive at 28.4x compared with the US Medical Equipment industry on 26.1x and a fair ratio of 22.2x. Is that premium justified or a warning sign?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and caution around LeMaitre Vascular leaves you unsure, now is a good time to review the data yourself and decide where you stand. To see what other investors view as the main positives, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond LeMaitre Vascular?

If LeMaitre Vascular has sharpened your focus, do not stop here. The best opportunities often sit just beyond the first stock that catches your attention.

• Spot potential mispricings early by checking out 52 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their underlying business strength.
• Prioritise resilience and sleep better at night by reviewing 83 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems that show solid fundamentals before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com